Drugs Made In America Acquisition (DMAAR) Assets (2024 - 2025)

Drugs Made In America Acquisition (DMAAR) posted Assets of $239.9 million for Q4 2025, up 0.96% on a QoQ basis from $237.6 million in Q3 2025, and up 43456.35% year-over-year from N/an in Q4 2024.

Drugs Made In America Acquisition (DMAAR) Assets (2024 - 2025) Analysis & Trends

Drugs Made In America Acquisition's Assets history runs 2 years deep, the most recent figure standing at $239.9 million for Q4 2025.

  • Quarterly Assets rose 43456.35% year-over-year to $239.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $239.9 million (up 43456.35% YoY) and the FY2025 annual result came in at $239.9 million, up 43456.35% from the prior year.
  • Assets was $239.9 million for Q4 2025 at Drugs Made In America Acquisition, up from $237.6 million in the prior quarter.
  • Across five years, Assets topped out at $239.9 million in Q4 2025 and bottomed at $550824.0 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Assets (Qtr)
1 SIM Acquisition Corp. I 314.52 Mn 314.52 Mn - 247.88 Mn
2 Thayer Ventures Acquisition 208.29 Mn 208.29 Mn - 206.82 Mn
3 Newbury Street II Acquisition 185.26 Mn 185.26 Mn - 184.11 Mn
4 Dynamix 178.78 Mn 178.78 Mn - 173.69 Mn
5 Hallmark Venture 103.01 Mn 102.76 Mn - 1,946.00
6 Voyager Acquisition 99.58 Mn 99.45 Mn - 270.06 Mn
7 Gores Holdings X 95.80 Mn 95.37 Mn - 374.60 Mn
8 Archimedes Tech SPAC Partners 89.88 Mn 89.88 Mn - 241.35 Mn
9 Cohen Circle Acquisition 80.05 Mn 80.05 Mn - 261.61 Mn
10 Drugs Made In America Acquisition 1.46 Mn 1.46 Mn - 239.92 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 239.92 Mn
Sep 30, 2025 237.63 Mn
Jun 30, 2025 235.21 Mn
Mar 31, 2025 232.81 Mn
Dec 31, 2024 550,824.00